New Risk • Jun 26
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩152.2b (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩152.2b market cap, or US$99.0m). Ankündigung • Mar 14
Bio Solution Co.,Ltd., Annual General Meeting, Mar 27, 2026 Bio Solution Co.,Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 232, gongneung-ro, nowon-gu, seoul South Korea New Risk • Nov 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change). New Risk • May 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Share price has been highly volatile over the past 3 months (13% average weekly change). Ankündigung • Mar 15
Bio Solution Co.,Ltd., Annual General Meeting, Mar 28, 2025 Bio Solution Co.,Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 232, gongneung-ro, nowon-gu, seoul South Korea New Risk • Mar 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (9.8% average weekly change). New Risk • May 31
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩137.2b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩137.2b market cap, or US$99.2m). New Risk • Apr 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (8.4% average weekly change). New Risk • Feb 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). New Risk • Jan 29
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩128.9b (US$96.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩128.9b market cap, or US$96.6m). New Risk • Aug 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported March 2021 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩102.9b market cap, or US$78.0m). Ankündigung • Sep 10
Biosolution Co.,Ltd. (KOSDAQ:A086820) agreed to acquire 9.6% stake in Kyperion Co., Ltd. for KRW 4.5 billion. Biosolution Co.,Ltd. (KOSDAQ:A086820) agreed to acquire 9.6% stake in Kyperion Co., Ltd. for KRW 4.5 billion on September 9, 2021. Kyperion Co., Ltd reported total revenues of KRW 309 million, total assets of KRW 5 billion , net loss of KRW 1.2 billion and total common equity of KRW 3 billion for the financial year ending December 31, 2020. The deal is expected o be completed by September 13, 2021. Ankündigung • Apr 18
Biosolution Co.,Ltd. announced that it expects to receive KRW 80 billion in funding from Eum Private Equity, IBK Capital Corporation Biosolution Co.,Ltd. (KOSDAQ:A086820) announced a private placement of round 1 Unregistered coupon nonguaranteed private convertible bonds for gross proceeds of KRW 80,000,000,000 on April 16, 2021. The transaction will include participation from Eum Private Equity and IBK Capital Corporation. The bonds bear an interest rate and yield to maturity of 3%, are issued at par and will mature on July 16, 2026. The bonds are fully convertible into 2,638,696 common shares representing 32.61% stake at a conversion price of KRW 30,318 per share from July 18, 2022 to July 15, 2026. The transaction has been approved by the board of directors of the company. The bonds are subject to prohibition of events and divisions for more than one year. The subscription date is on April 20, 2021 and the payment date is on July 16, 2021. Is New 90 Day High Low • Feb 24
New 90-day low: ₩26,100 The company is down 14% from its price of ₩30,450 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. Is New 90 Day High Low • Nov 24
New 90-day high: ₩31,650 The company is up 14% from its price of ₩27,800 on 27 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 3.0% over the same period. Is New 90 Day High Low • Oct 16
New 90-day low: ₩24,000 The company is down 14% from its price of ₩27,800 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. Is New 90 Day High Low • Sep 22
New 90-day low: ₩26,200 The company is down 17% from its price of ₩31,400 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 8.0% over the same period. 
